Core Viewpoint - Heng Rui Medicine (600276) has received approval from the National Medical Products Administration for clinical trials of HRS9531 injection, a novel dual agonist targeting GIPR and GLP-1R with global intellectual property rights [1] Group 1: Product Development - The HRS9531 injection is designed to regulate glucose and lipid metabolism, suppress appetite, and enhance insulin sensitivity, thereby improving blood sugar levels and aiding weight loss [1] - The injection is expected to provide comprehensive benefits for patients with metabolic dysfunction-related fatty liver disease (MASH) by improving liver lipid accumulation, reducing inflammation, and potentially improving liver fibrosis [1] - There are currently no similar drugs approved for the MASH indication globally, indicating a unique market opportunity for the company [1]

财经频道更多独家策划、专家专栏，免费查阅>> 责任编辑：钟离 格隆汇12月12日丨恒瑞医药(600276.SH)公布，公司子公司福建盛迪医药有限公司收到国家药品监督管 理局核准签发关于HRS9531注射液的《药物临床试验批准通知书》，将于近期开展临床试验。 HRS9531注射液是以HRS9531为主要活性成分，具有全球自主知识产权的新型靶向抑胃肽受体 （GIPR）和胰高血糖素样肽-1受体（GLP-1R）的双激动剂，可在体内调节糖脂代谢、抑制食欲和增强 胰岛素敏感性，从而起到改善血糖和减轻体重的效果。对于代谢功能障碍相关脂肪性肝炎（MASH）患 者，HRS9531注射液有望通过改善肝脏脂质堆积、减轻炎症反应及潜在改善肝纤维化带来综合获益。 ...